Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Evaluation of the potential for QTc prolongation with avelumab.

Vugmeyster Y, Güzel G, Hennessy M, Loos AH, Dai H.

Cancer Chemother Pharmacol. 2019 Sep 3. doi: 10.1007/s00280-019-03925-z. [Epub ahead of print]

PMID:
31478078
2.

An atypical aspartic protease modulates lateral root development in Arabidopsis thaliana.

Soares A, Niedermaier S, Faro R, Loos A, Manadas B, Faro C, Huesgen PF, Cheung AY, Simões I.

J Exp Bot. 2019 Apr 12;70(7):2157-2171. doi: 10.1093/jxb/erz059.

PMID:
30778561
3.

Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.

Hendrix N, Ollendorf DA, Chapman RH, Loos A, Liu S, Kumar V, Linder JA, Pearson SD, Veenstra DL.

J Manag Care Spec Pharm. 2018 Dec;24(12):1210-1217. doi: 10.18553/jmcp.2018.24.12.1210.

4.

On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies.

Unkel S, Amiri M, Benda N, Beyersmann J, Knoerzer D, Kupas K, Langer F, Leverkus F, Loos A, Ose C, Proctor T, Schmoor C, Schwenke C, Skipka G, Unnebrink K, Voss F, Friede T.

Pharm Stat. 2019 Mar;18(2):166-183. doi: 10.1002/pst.1915. Epub 2018 Nov 20.

5.

Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.

Zimmermann M, Brouwer E, Tice JA, Seidner M, Loos AM, Liu S, Chapman RH, Kumar V, Carlson JJ.

CNS Drugs. 2018 Dec;32(12):1145-1157. doi: 10.1007/s40263-018-0566-9.

PMID:
30141001
6.

Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.

Kelly K, Infante JR, Taylor MH, Patel MR, Wong DJ, Iannotti N, Mehnert JM, Loos AH, Koch H, Speit I, Gulley JL.

Cancer. 2018 May 1;124(9):2010-2017. doi: 10.1002/cncr.31293. Epub 2018 Feb 22.

7.

Free Monoterpene Isomer Profiles of Vitis Vinifera L. cv. White Wines.

Song M, Fuentes C, Loos A, Tomasino E.

Foods. 2018 Feb 21;7(2). pii: E27. doi: 10.3390/foods7020027.

8.

Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.

J Am Acad Dermatol. 2018 Jul;79(1):135-144.e7. doi: 10.1016/j.jaad.2018.02.027. Epub 2018 Feb 10.

PMID:
29438757
9.

Automated face detection for occurrence and occupancy estimation in chimpanzees.

Crunchant AS, Egerer M, Loos A, Burghardt T, Zuberbühler K, Corogenes K, Leinert V, Kulik L, Kühl HS.

Am J Primatol. 2017 Mar;79(3):1-12. doi: 10.1002/ajp.22627. Epub 2017 Jan 17.

PMID:
28095593
10.

Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.

Samur S, Klebanoff M, Banken R, Pratt DS, Chapman R, Ollendorf DA, Loos AM, Corey K, Hur C, Chhatwal J.

Hepatology. 2017 Mar;65(3):920-928. doi: 10.1002/hep.28932. Epub 2017 Jan 17.

PMID:
27906472
11.

A novel tool for stable nitrogen isotope analysis in aqueous samples.

Federherr E, Kupka HJ, Cerli C, Kalbitz K, Dunsbach R, Loos A, de Reus M, Lange L, Panetta RJ, Schmidt TC.

Rapid Commun Mass Spectrom. 2016 Dec 15;30(23):2537-2544. doi: 10.1002/rcm.7740.

PMID:
27619634
12.

Magnesium alloys: A stony pathway from intensive research to clinical reality. Different test methods and approval-related considerations.

Willbold E, Weizbauer A, Loos A, Seitz JM, Angrisani N, Windhagen H, Reifenrath J.

J Biomed Mater Res A. 2017 Jan;105(1):329-347. doi: 10.1002/jbm.a.35893. Epub 2016 Nov 18. Review.

PMID:
27596336
13.

Vacuolar targeting of recombinant antibodies in Nicotiana benthamiana.

Ocampo CG, Lareu JF, Marin Viegas VS, Mangano S, Loos A, Steinkellner H, Petruccelli S.

Plant Biotechnol J. 2016 Dec;14(12):2265-2275. doi: 10.1111/pbi.12580. Epub 2016 Jun 14.

14.

Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants.

Loos A, Gach JS, Hackl T, Maresch D, Henkel T, Porodko A, Bui-Minh D, Sommeregger W, Wozniak-Knopp G, Forthal DN, Altmann F, Steinkellner H, Mach L.

Proc Natl Acad Sci U S A. 2015 Oct 13;112(41):12675-80. doi: 10.1073/pnas.1509090112. Epub 2015 Sep 28.

15.

Transient Glyco-Engineering of N. benthamiana Aiming at the Synthesis of Multi-antennary Sialylated Proteins.

Loos A, Castilho A.

Methods Mol Biol. 2015;1321:233-48. doi: 10.1007/978-1-4939-2760-9_17.

PMID:
26082227
16.

Plant glyco-biotechnology on the way to synthetic biology.

Loos A, Steinkellner H.

Front Plant Sci. 2014 Oct 8;5:523. doi: 10.3389/fpls.2014.00523. eCollection 2014. Review.

17.

Structural and functional characterization of an anti-West Nile virus monoclonal antibody and its single-chain variant produced in glycoengineered plants.

Lai H, He J, Hurtado J, Stahnke J, Fuchs A, Mehlhop E, Gorlatov S, Loos A, Diamond MS, Chen Q.

Plant Biotechnol J. 2014 Oct;12(8):1098-107. doi: 10.1111/pbi.12217. Epub 2014 Jun 29.

18.

Expression and glycoengineering of functionally active heteromultimeric IgM in plants.

Loos A, Gruber C, Altmann F, Mehofer U, Hensel F, Grandits M, Oostenbrink C, Stadlmayr G, Furtmüller PG, Steinkellner H.

Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6263-8. doi: 10.1073/pnas.1320544111. Epub 2014 Mar 31.

19.

The human anti-HIV antibodies 2F5, 2G12, and PG9 differ in their susceptibility to proteolytic degradation: down-regulation of endogenous serine and cysteine proteinase activities could improve antibody production in plant-based expression platforms.

Niemer M, Mehofer U, Torres Acosta JA, Verdianz M, Henkel T, Loos A, Strasser R, Maresch D, Rademacher T, Steinkellner H, Mach L.

Biotechnol J. 2014 Apr;9(4):493-500. doi: 10.1002/biot.201300207.

20.

Expression of human butyrylcholinesterase with an engineered glycosylation profile resembling the plasma-derived orthologue.

Schneider JD, Castilho A, Neumann L, Altmann F, Loos A, Kannan L, Mor TS, Steinkellner H.

Biotechnol J. 2014 Apr;9(4):501-10. doi: 10.1002/biot.201300229. Epub 2013 Nov 8.

21.

Gold(I) complexes of tetrathiaheterohelicene phosphanes.

Cauteruccio S, Loos A, Bossi A, Blanco Jaimes MC, Dova D, Rominger F, Prager S, Dreuw A, Licandro E, Hashmi AS.

Inorg Chem. 2013 Jul 15;52(14):7995-8004. doi: 10.1021/ic4005533. Epub 2013 Jul 1.

PMID:
23815095
22.

N-glycosylation of plant-produced recombinant proteins.

Bosch D, Castilho A, Loos A, Schots A, Steinkellner H.

Curr Pharm Des. 2013;19(31):5503-12. Review.

PMID:
23394562
23.

Utility of the P19 suppressor of gene-silencing protein for production of therapeutic antibodies in Nicotiana expression hosts.

Garabagi F, Gilbert E, Loos A, McLean MD, Hall JC.

Plant Biotechnol J. 2012 Dec;10(9):1118-28. doi: 10.1111/j.1467-7652.2012.00742.x. Epub 2012 Sep 17.

24.

IgG-Fc glycoengineering in non-mammalian expression hosts.

Loos A, Steinkellner H.

Arch Biochem Biophys. 2012 Oct 15;526(2):167-73. doi: 10.1016/j.abb.2012.05.011. Epub 2012 May 23. Review.

25.

Cytotoxicity and ion release of alloy nanoparticles.

Hahn A, Fuhlrott J, Loos A, Barcikowski S.

J Nanopart Res. 2012 Jan;14(1):1-10. Epub 2012 Jan 12.

26.

Identification of novel genes in Hirschsprung disease pathway using whole genome expression study.

Saeed A, Barreto L, Neogii SG, Loos A, McFarlane I, Aslam A.

J Pediatr Surg. 2012 Feb;47(2):303-7. doi: 10.1016/j.jpedsurg.2011.11.017.

PMID:
22325380
27.

Expression of antibody fragments with a controlled N-glycosylation pattern and induction of endoplasmic reticulum-derived vesicles in seeds of Arabidopsis.

Loos A, Van Droogenbroeck B, Hillmer S, Grass J, Pabst M, Castilho A, Kunert R, Liang M, Arcalis E, Robinson DG, Depicker A, Steinkellner H.

Plant Physiol. 2011 Apr;155(4):2036-48. doi: 10.1104/pp.110.171330. Epub 2011 Feb 16.

28.

Maltose- and maltotriose-modified, hyperbranched poly(ethylene imine)s (OM-PEIs): Physicochemical and biological properties of DNA and siRNA complexes.

Höbel S, Loos A, Appelhans D, Schwarz S, Seidel J, Voit B, Aigner A.

J Control Release. 2011 Jan 20;149(2):146-58. doi: 10.1016/j.jconrel.2010.10.008. Epub 2010 Oct 11.

PMID:
20946922
29.

Production of monoclonal antibodies with a controlled N-glycosylation pattern in seeds of Arabidopsis thaliana.

Loos A, Van Droogenbroeck B, Hillmer S, Grass J, Kunert R, Cao J, Robinson DG, Depicker A, Steinkellner H.

Plant Biotechnol J. 2011 Feb;9(2):179-92. doi: 10.1111/j.1467-7652.2010.00540.x.

30.

Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication.

Siena S, Glynne-Jones R, Adenis A, Thaler J, Preusser P, Aguilar EA, Aapro MS, Loos AH, Esser R, Wilke H.

Cancer. 2010 Apr 1;116(7):1827-37. doi: 10.1002/cncr.24945.

31.

A [4+2] mixed ligand approach to ruthenium DNA metallointercalators [Ru(tpa)(N-N)](PF(6))(2) using a tris(2-pyridylmethyl)amine (tpa) capping ligand.

Kraft SS, Bischof C, Loos A, Braun S, Jafarova N, Schatzschneider U.

J Inorg Biochem. 2009 Aug;103(8):1126-34. doi: 10.1016/j.jinorgbio.2009.05.013. Epub 2009 May 24.

PMID:
19540597
32.

Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.

Raoul JL, Van Laethem JL, Peeters M, Brezault C, Husseini F, Cals L, Nippgen J, Loos AH, Rougier P.

BMC Cancer. 2009 Apr 14;9:112. doi: 10.1186/1471-2407-9-112.

33.

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P.

J Clin Oncol. 2009 Feb 10;27(5):663-71. doi: 10.1200/JCO.2008.20.8397. Epub 2008 Dec 29.

34.

Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.

Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, Aapro MS, Esser R, Loos AH, Siena S.

J Clin Oncol. 2008 Nov 20;26(33):5335-43. doi: 10.1200/JCO.2008.16.3758. Epub 2008 Oct 14.

PMID:
18854570
35.

Transplanted human cord blood-derived unrestricted somatic stem cells improve left-ventricular function and prevent left-ventricular dilation and scar formation after acute myocardial infarction.

Ghodsizad A, Niehaus M, Kögler G, Martin U, Wernet P, Bara C, Khaladj N, Loos A, Makoui M, Thiele J, Mengel M, Karck M, Klein HM, Haverich A, Ruhparwar A.

Heart. 2009 Jan;95(1):27-35. doi: 10.1136/hrt.2007.139329. Epub 2008 Jun 2.

PMID:
18519547
36.

A proteomic study of the major allergens from yellow jacket venoms.

Kolarich D, Loos A, Léonard R, Mach L, Marzban G, Hemmer W, Altmann F.

Proteomics. 2007 May;7(10):1615-23.

PMID:
17443842
37.

Nerve growth factor-induced phosphorylation of amphiphysin-1 by casein kinase 2 regulates clathrin-amphiphysin interactions.

Döring M, Loos A, Schrader N, Pfander B, Bauerfeind R.

J Neurochem. 2006 Sep;98(6):2013-22.

38.

Cancer consequences of the Chernobyl accident: 20 years on.

Cardis E, Howe G, Ron E, Bebeshko V, Bogdanova T, Bouville A, Carr Z, Chumak V, Davis S, Demidchik Y, Drozdovitch V, Gentner N, Gudzenko N, Hatch M, Ivanov V, Jacob P, Kapitonova E, Kenigsberg Y, Kesminiene A, Kopecky KJ, Kryuchkov V, Loos A, Pinchera A, Reiners C, Repacholi M, Shibata Y, Shore RE, Thomas G, Tirmarche M, Yamashita S, Zvonova I.

J Radiol Prot. 2006 Jun;26(2):127-40. Epub 2006 Apr 24. Review.

PMID:
16738412
39.

Potential of Rhodococcus strains for biotechnological vanillin production from ferulic acid and eugenol.

Plaggenborg R, Overhage J, Loos A, Archer JA, Lessard P, Sinskey AJ, Steinbüchel A, Priefert H.

Appl Microbiol Biotechnol. 2006 Oct;72(4):745-55. Epub 2006 Jan 19.

PMID:
16421716
40.

Transformation of organoarsenical species by the microflora of freshwater crayfish.

Devesa V, Loos A, Súñer MA, Vélez D, Feria A, Martínez A, Montoro R, Sanz Y.

J Agric Food Chem. 2005 Dec 28;53(26):10297-305.

PMID:
16366730
41.

Microbiological quality of carbonated drinking water produced with in-home carbonation systems.

Kohnen W, Teske-Keiser S, Meyer HG, Loos AH, Pietsch M, Jansen B.

Int J Hyg Environ Health. 2005;208(5):415-23.

PMID:
16217926
42.
43.

Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening.

Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Møller H, Hakama M, Parkin DM.

Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):677-86.

44.

Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes.

Fliser D, Wagner KK, Loos A, Tsikas D, Haller H.

J Am Soc Nephrol. 2005 Apr;16(4):1135-40. Epub 2005 Feb 16.

45.
46.
47.

Ovarian cancer in Europe: Cross-sectional trends in incidence and mortality in 28 countries, 1953-2000.

Bray F, Loos AH, Tognazzo S, La Vecchia C.

Int J Cancer. 2005 Mar 1;113(6):977-90.

48.

[Reconstruction of the extensor pollicis longus tendon by transposition of the extensor indicis tendon].

Loos A, Kalb K, Van Schoonhoven J, Landsleitner Dagger B.

Handchir Mikrochir Plast Chir. 2003 Dec;35(6):368-72. German.

PMID:
14681768
49.

Risk factors influencing the outcome after surgical treatment of complicated deep sternal wound complications.

Peivandi AA, Kasper-König W, Quinkenstein E, Loos AH, Dahm M.

Cardiovasc Surg. 2003 Jun;11(3):207-12.

PMID:
12704330
50.

Disparity between changes in mRNA abundance and enzyme activity in Corynebacterium glutamicum: implications for DNA microarray analysis.

Glanemann C, Loos A, Gorret N, Willis LB, O'Brien XM, Lessard PA, Sinskey AJ.

Appl Microbiol Biotechnol. 2003 Mar;61(1):61-8. Epub 2002 Dec 21.

PMID:
12658516

Supplemental Content

Support Center